Streamlined production of 100+ barcoded rAAV capsid variants for preclinical studies

Producing diverse, engineered AAV capsid libraries for preclinical study evaluation has traditionally been slow and resource-intensive. Revvity’s innovative small-scale production platform overcomes these bottlenecks with parallelized, cost-effective workflows that deliver 105 individually barcoded rAAV capsid variants in as little as four weeks—each ready for pooled biodistribution studies in non-human primates.

Features:

• High-throughput, cost-efficient manufacturing: Parallel production of up to 36 variants per day using HEK293 suspension cultures.
• Robust yields and purity: Achieve ≥1.3×10¹⁰ vector genomes per variant with density-based purification workflows.
• Barcode-enabled pooled evaluation: Individual variant identification supports complex biodistribution studies in NHP models.
• Automation-ready process: Integration with liquid handling systems and mini-bioreactors to reduce errors and labor costs.
• Accelerated timelines: Manufacture over 100 rAAV variants in approximately four weeks, supporting rapid preclinical study development.

For research use only. Not for use in diagnostic procedures